Cosibelimab, sold under the brand name Unloxcyt, is a monoclonal antibody used for the treatment of cutaneous squamous-cell carcinoma. It is a programmed...
7 KB (365 words) - 07:42, 31 December 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
37 KB (3,216 words) - 05:38, 25 November 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
46 KB (4,813 words) - 05:44, 28 December 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
7 KB (364 words) - 07:33, 28 December 2024
Cortone Cortril Cortrophin-Zinc Cortrosyn Corvert Coryphen Codeine Corzide cosibelimab (USAN, INN) cositecan (USAN, INN) Cosmegen CosmoFer Cosopt Cotazym Cotellic...
7 KB (430 words) - 08:49, 27 December 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
89 KB (8,650 words) - 10:59, 2 January 2025
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
9 KB (603 words) - 00:28, 30 September 2024
comparing the effectiveness of different treatments for non-metastatic cSCC. Cosibelimab (Unloxcyt) was approved for medical use in the United States in December...
54 KB (5,469 words) - 04:33, 30 December 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
28 KB (2,734 words) - 08:20, 27 December 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
13 KB (1,060 words) - 00:29, 30 September 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
15 KB (1,447 words) - 00:31, 30 September 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
9 KB (460 words) - 00:28, 30 September 2024
Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Cosibelimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab...
12 KB (821 words) - 06:14, 23 December 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
2 KB (160 words) - 19:37, 6 November 2024
Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
43 KB (4,183 words) - 04:17, 1 October 2024
list 70". WHO Drug Information. 27 (3). hdl:10665/331167. "FDA approves cosibelimab-ipdl". U.S. Food and Drug Administration (FDA). 13 December 2024. Retrieved...
138 KB (4,154 words) - 05:18, 17 December 2024
formulation currently under clinical evaluations in the US, China, and Japan Cosibelimab (CK-301) by Checkpoint Therapeutics is a PD-L1 inhibitor developed by...
35 KB (3,450 words) - 03:38, 30 September 2024
Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Cosibelimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab...
12 KB (758 words) - 23:46, 14 March 2024
(+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Cosibelimab Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
5 KB (368 words) - 15:29, 21 August 2024
(+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Cosibelimab Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
4 KB (241 words) - 13:42, 14 July 2024
(+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Cosibelimab Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab vedotin...
3 KB (129 words) - 01:04, 19 July 2023